BVS: Comparable to Second-Generation DES in Complex Lesions

BVS Comparable to Second-Generation DESA center carrying out a mid- to long-term follow-up of the performance of everolimus-eluting bioresorbable scaffolds (Absorb) observed that this new device has an acceptable rate of major cardiovascular events, when compared to second-generation drug-eluting stents.

Furthermore, although the population was complex and non-selected, no cases of early thrombosis were reported.

This study enrolled 249 patients as part of the BVS Expand registry. Only 5 patients, in whom device implantation was rendered impossible, were excluded from the analysis.

After a year, 5.1% of the population suffered from cardiac mortality, myocardial infarction, and/or target lesion revascularization, major adverse cardiac events (MACE).

Using Kaplan-Meier estimates, the MACE rate at 18 months was 6.8%, with myocardial infarction as the most common event.

Considering MACE components separately, the rates of cardiac mortality, myocardial infarction and target lesion revascularization were 1.8%, 5.2%, and 4.0%, respectively.

The definite scaffold thrombosis rate was 1.9%; no cases of acute, sub-acute or late thrombosis were observed.

The univariate analysis lacked the statistical power to show significant thrombosis predictors, but a certain trend was observed for some variables such as age, long lesions, calcified lesions, and small vessels (reference diameter <2.5 mm).

These findings would support the use of Absorb in complex anatomies; however, the fact that, in 39% of patients, intravascular ultrasound (IVUS) and optical coherence tomography (OCT) were used for the optimization of device implantation should be taken into account.

 

Conclusion

The everolimus-eluting bioresorbable scaffold (Absorb) showed acceptable long-term performance, even while being assessed on a population presenting complex lesions. No cases of acute or sub-acute thrombosis were observed.

 

Editorial

Several previous works have warned about the need of a thorough implantation protocol for these new devices.

In this study, the strategy always included predilatation, the implantation of a device whose diameter matched that of the reference vessel, and postdilatation. The avoidance of small vessels and ostial lesions was also recommended. Taking all these precautions, a significant reduction of the scaffold thrombosis rate, from 3% to 1% annual, is possible.

The unique advantages of a bioresorbable scaffold are likely to appear once the device has been fully resorbed; their observation would require a follow-up of at least 36 months, instead of just 18.

 

Original title: Mid- to long-term clinical outcomes of patients treated with the everolimus-eluting bioresorbable vascular scaffold: the BVS Expand registry.

Reference: Felix CM et al. J Am Coll Cardiol Intv. 2016; Epub ahead of print.

 

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...